Chemical constituents from Bambusae concretio Silicea and their anti-renal fibrosis activity

IF 1.3 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2024-10-31 DOI:10.1016/j.phytol.2024.10.004

Hong Zhou , Ye-Fei Chen , Bin-Yuan Hu , Qing-Qian Zeng , Yong-Xian Cheng

引用次数: 0

Abstract

Two pairs of undescribed phenylpropanoids derivatives (±)-1 and (±)-2 together with sixteen known compounds (3–18) were isolated from the resin Bambusae concretio Silicea. Their structures were identified by spectroscopic analyses and computational methods. Furthermore, the anti-renal fibrosis activities of the new compounds were evaluated in transforming growth factor beta 1 (TGF-β1) stimulated NRK-52e cells by western blotting. As a result, compounds (±)-1 and (±)-2 were found to exhibit a dose-dependent inhibition of α-SMA, collagen I, and fibronectin expression in TGF-β1 stimulated NRK-52e cells.

查看原文本刊更多论文

Bambusae concretio Silicea 的化学成分及其抗肾脏纤维化活性

从树脂 Bambusae concretio Silicea 中分离出了两对未曾描述过的苯基丙烷衍生物 (±)-1 和 (±)-2 以及 16 个已知化合物 (3-18)。通过光谱分析和计算方法确定了它们的结构。此外，新化合物在转化生长因子β1（TGF-β1）刺激的 NRK-52e 细胞中的抗肾脏纤维化活性也通过 Western 印迹法进行了评估。结果发现，(±)-1和(±)-2化合物对TGF-β1刺激的NRK-52e细胞中的α-SMA、胶原蛋白I和纤连蛋白的表达具有剂量依赖性抑制作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.